Pathogen Immunity, Signalling and Therapeutic Applications (PISTA)
The team focuses its research programme on the characterisation of infectious diseases and the development of new therapeutic strategies against these diseases and emerging infectious threats
The goal of the Pathogen Immunity Signalling and Therapeutic Applications (PISTA) group is to understand the underlying biology and features of human infection so as to develop novel therapeutic strategies against upcoming threats in a world that is becoming vulnerable to emerging pathogens that thrive due to globalization and climate change trends. As an emerging group studying emerging viruses, the team aims to lead rational design of broad antiviral treatments so as to fortify and strengthen preparedness against new viral threats, given that while infectious diseases can be contained by host defences, pathogens evolve to overcome immunity. In their endeavour to develop innovative antiviral strategies against microbial threats, the group collaborates with a range of clinical researchers, academic partners, and industries.
-
-
-
Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides.
Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.
Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.
Immune responses associated with mpox viral clearance in men with and without HIV in Spain: a multisite, observational, prospective cohort study.
Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.
-
-
News from the group
A pioneering study compares the immune response to mpox in people with and without HIV
